Gilead Focuses On Researching HIV, Hepatitis B Treatments After Success Finding HCV Cure
Bloomberg Business: After Curing Hepatitis C, Gilead Works to Vanquish More Viruses
“Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B. Even with some promising signs in early trials, the biggest biotechnology firm in the world faces long odds in finding a way to rid humanity of the diseases…” (Chen, 8/17).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.